GlassScriptPhysician profile
Jack V Pinto
NPI 1992714034
$87,337.19
in general payments reported to CMS, 2019-2025
41 companies · $2,379 in 2025
The $2,379 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $8,753 · 2021: $15K · 2022: $14K · 2023: $21K · 2024: $9,950 · 2025: $2,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $4,966 · Travel and Lodging: $1,223 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,000.00 |
| Food and Beverage | $4,966.47 |
| Travel and Lodging | $1,223.42 |
| Education | $190.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $76,541.04 | 2019-2025 | Watchman Access System, Stingray, Watchman Flx |
| Medtronic, INC. | $1,644.66 | 2021-2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $934.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $913.53 | 2020-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.87 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $641.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $634.35 | 2019-2024 | Xarelto |
| Amgen INC. | $450.23 | 2019-2025 | Repatha, Repatha |
| Abiomed | $354.89 | 2022-2025 | Impella |
| Novo Nordisk INC | $348.86 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic Vascular, INC. | $340.42 | 2019 | |
| Preventric Diagnostics, INC. | $332.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $312.07 | 2021-2025 | Lokelma, Farxiga, Wainua |
| Siemens Medical Solutions USA, INC. | $288.54 | 2021 | |
| Merck Sharp & Dohme LLC | $215.26 | 2021-2025 | Verquvo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $211.08 | 2022-2025 | Biomonitor |
| Edwards Lifesciences Corporation | $196.86 | 2023-2025 | Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $193.73 | 2020-2025 | Nexletol |
| W. L. Gore & Associates, INC. | $192.57 | 2020 | |
| Astellas Pharma US INC | $190.98 | 2023 | |
| Sanofi-Aventis U.S. LLC | $177.67 | 2021-2023 | |
| Abbott Laboratories | $163.32 | 2019-2025 | Cardiomems, Diamondback Coronary |
| Pfizer INC. | $156.45 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $154.38 | 2023-2024 | Inpefa |
| Heartflow, INC. | $130.90 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $130.31 | 2019-2024 | Praluent, Evkeeza |
| Angiodynamics, INC. | $91.83 | 2021-2023 | Venacure 1470 Pro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.50 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $71.17 | 2021-2025 | |
| Azurity Pharmaceuticals, INC. | $64.98 | 2023-2024 | Edarbi, Edarbi |
| Impulse Dynamics (USA) INC. | $64.08 | 2023-2024 | Optimizer, Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $59.46 | 2024 | Arcalyst |
| Infobionic, INC | $57.29 | 2020 | |
| Alnylam Pharmaceuticals INC. | $56.08 | 2022-2024 | Onpattro |
| Arbor Pharmaceuticals, INC. | $50.07 | 2019-2021 | |
| Biocompatibles, INC. | $40.30 | 2019 | |
| Intuitive Surgical, INC. | $37.26 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $26.16 | 2019-2020 | |
| Cmp Pharma, INC. | $24.58 | 2020 | |
| Terumo Medical Corporation | $19.49 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.